Merck's Keytruda faces delay in first-line approval decision

The Food and Drug Administration has delayed a decision on approval of Merck & Co.'s Keytruda as monotherapy in first-line treatment of locally advanced or metastatic PD-L1-expressing non-small cell lung cancer (NSCLC). The new action date, pushed back by three months, will be April 11, 2019.